DOI:
10.1055/s-00000068
Seminars in Interventional Radiology
LinksClose Window
References
Finn RS, Ryoo BY, Merle P. et al. KEYNOTE-240 Investigators.
Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial.
J Clin Oncol 2020;
38 (03) 193-202
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.